Scholarlink

Background <p>The oncologic safety of preoperative controlled ovarian stimulation (COS) for fertility preservation in women with an in situ estrogen receptor positive (ER+) breast cancer is unclear. The purpose of this study was to compare oncologic outcomes of women with ER+ breast cancer undergoing preoperative COS versus (1) postoperative COS or (2) matched controls not undergoing COS.</p> Patients and Methods <p>This was a single-institution retrospective cohort study of&#xa0;women with ER+ breast cancer receiving oncofertility counseling who pursued COS from&#xa0;2014–2024.&#xa0;The primary outcome was progression-free survival (PFS). A subcohort of patients who&#xa0;received&#xa0;neoadjuvant systemic therapy was compared with a matched cohort of similar patients with ER+ breast cancer who did not undergo COS.&#xa0;Propensity score matching criteria were age, HER2 receptor status, and clinical stage.</p> Results <p>Among 51 women with ER+ breast cancer undergoing COS, the median follow-up was 5.5 years.&#xa0;5-year PFS was similar for preoperative COS (<i>n</i> = 32) versus postoperative COS (<i>n</i> = 19): 94.1% (95% CI 65.0–99.2%) versus 93.3% (95% CI 61.3–99.0%), <i>p</i> = 0.73. Patients undergoing neoadjuvant systemic therapy (NST) and preoperative COS (<i>n</i> = 30) experienced a significantly longer time from diagnosis to NST initiation than propensity-score matches who did not undergo COS (48 versus 29.5 days, <i>p</i> &lt; 0.0001), but disease-free survival was similar: 94.1% (95% CI 65.0–99.2%) versus 93.3% (95% CI 75.9–98.3%), <i>p</i> = 0.15.</p> Conclusions <p>In this study of women with ER+ breast cancers, preoperative COS was not associated with increased risks of disease progression or death. While COS was associated with a modest delay in NST initiation, PFS was similar to propensity-score matched patients who did not undergo COS. Results support the oncologic safety of COS in the setting of an in situ ER+ tumor and provide much-needed evidence for young women with breast cancer receiving gonadotoxic NST who desire future childbearing during survivorship.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Oncologic Safety of Preoperative Controlled Ovarian Stimulation for Fertility Preservation Among Women with Estrogen Receptor Positive Breast Cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月5日

查看全文
  • Jennifer H. Chen,
  • Irene Peregrin-Alvarez,
  • Carla L. Warneke,
  • Laurie J. McKenzie,
  • Terri L. Woodard,
  • Helen M. Johnson

摘要

Background

The oncologic safety of preoperative controlled ovarian stimulation (COS) for fertility preservation in women with an in situ estrogen receptor positive (ER+) breast cancer is unclear. The purpose of this study was to compare oncologic outcomes of women with ER+ breast cancer undergoing preoperative COS versus (1) postoperative COS or (2) matched controls not undergoing COS.

Patients and Methods

This was a single-institution retrospective cohort study of women with ER+ breast cancer receiving oncofertility counseling who pursued COS from 2014–2024. The primary outcome was progression-free survival (PFS). A subcohort of patients who received neoadjuvant systemic therapy was compared with a matched cohort of similar patients with ER+ breast cancer who did not undergo COS. Propensity score matching criteria were age, HER2 receptor status, and clinical stage.

Results

Among 51 women with ER+ breast cancer undergoing COS, the median follow-up was 5.5 years. 5-year PFS was similar for preoperative COS (n = 32) versus postoperative COS (n = 19): 94.1% (95% CI 65.0–99.2%) versus 93.3% (95% CI 61.3–99.0%), p = 0.73. Patients undergoing neoadjuvant systemic therapy (NST) and preoperative COS (n = 30) experienced a significantly longer time from diagnosis to NST initiation than propensity-score matches who did not undergo COS (48 versus 29.5 days, p < 0.0001), but disease-free survival was similar: 94.1% (95% CI 65.0–99.2%) versus 93.3% (95% CI 75.9–98.3%), p = 0.15.

Conclusions

In this study of women with ER+ breast cancers, preoperative COS was not associated with increased risks of disease progression or death. While COS was associated with a modest delay in NST initiation, PFS was similar to propensity-score matched patients who did not undergo COS. Results support the oncologic safety of COS in the setting of an in situ ER+ tumor and provide much-needed evidence for young women with breast cancer receiving gonadotoxic NST who desire future childbearing during survivorship.